Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology
Shots:
- Bayer to get non-exclusive WW license rights to develop and commercialize its own products by using ProteoNic’s 2G UNic Technology
- The focus of the collaboration is to produce and enhance Bayer recombinant proteins portfolio utilizing ProteoNic’s 2G UNic Technology
- ProteoNic’s 2G UNic Technology is a protein expression technology designed to improve cell line production levels exerting effects on recombinant protein production
Ref: ProteoNic Biotechnology | Image: AgNewsWire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
